Clinical Trials
18 trialsNCT00544115 2026-06-02
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00611351 2023-10-23
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Phase 2 Completed
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00303719 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00053989 2020-02-10
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Roswell Park Cancer Institute
Phase 2 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT01116232 2019-03-26
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00453206 2018-09-10
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Wake Forest University Health Sciences
Phase NA Completed
NCT00619645 2018-01-10
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
University of California, Davis
Phase 2 Completed
NCT00245037 2017-09-27
Bu Flu TBI
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00448357 2017-07-17
LCCC0510
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00448201 2017-05-30
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00513474 2017-05-25
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT01118013 2017-03-24
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00079391 2015-10-26
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00589563 2014-09-10
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00027560 2013-01-07
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed